Resmed (RMD) Non-Current Deffered Revenue (2010 - 2026)

Resmed's Non-Current Deffered Revenue history runs 17 years deep, the most recent figure standing at $163.1 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 7.98% year-over-year to $163.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.1 million (up 7.98% YoY) and the FY2025 annual result came in at $156.8 million, up 14.17% from the prior year.
• Non-Current Deffered Revenue was $163.1 million for Q1 2026 at Resmed, up from $159.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $163.1 million in Q1 2026 and bottomed at $94.1 million in Q1 2022.
• A 5-year average of $130.4 million and a median of $132.0 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue grew 4.33% — and 2023, when it climbed 24.86%.
• Resmed's Non-Current Deffered Revenue stood at $102.8 million in 2022, then increased by 23.94% to $127.4 million in 2023, then grew by 14.99% to $146.5 million in 2024, then rose by 9.06% to $159.8 million in 2025, then increased by 2.1% to $163.1 million in 2026.
• Business Quant data shows RMD's Non-Current Deffered Revenue at $163.1 million in Q1 2026, $159.8 million in Q4 2025, and $159.4 million in Q3 2025.